

New Frontiers in 3D Cell Culture-based Screening Technologies

Towards greater physiological relevance

October 13, 2016

Johns Hopkins University, Baltimore, MD, USA

Register Now!

www.insphero.com/new-frontiers-in-3d-conference

A global forum for the advancement of 3D model systems, featuring insight from regulatory, industry, and academic leaders

8 Great Reasons to Participate

Who should attend

Regulatory

Industry

Academic

- 1 Discover how 3D cell culture models are being utilized in industry, and where they are making the greatest translational impact
- 2 Understand regulatory standards and best practices as models evolve into greater use and acceptance
- 3 Learn how 3D cell culture models are advancing safety and investigational toxicity testing towards more predictive, translatable results
- 4 Understand how 3D cell culture models can improve target identification and validation
- 5 Discuss the challenges and successes of integrating 3D cell culture models with thought leaders from around the world
- 6 Gain an international industrial perspective on current progress in the field of complex *in vitro* model systems
- 7 Share your experience in practical application of 3D models, and their incorporation into your investigative strategies
- 8 Network with colleagues from international industry, academic, and regulatory agencies



Important Dates

Podium Presentation Deadline: August 1, 2016

Poster Abstract Deadline: August 15, 2016

Shape the discussion

Podium abstract deadline August 1, 2016

Advanced 3D tissue models are changing the shape of *in vitro* testing for drug discovery and development from flat, monolayer cell culture to more complex 3D systems providing greater physiological relevance. The inaugural New Frontiers Conference establishes an international forum in which to discuss integration of advanced 3D models throughout the drug discovery and development process, with an emphasis on translational approaches, challenges, and successes.

Featured Speakers

Drug Discovery



New Systems to Analyze the Complexity of Drug Resistance in Cancer
by Michael Gottesman, MD of Center for Cancer Research, NCI, NIH



Implementing 3D Phenotypic and Target Based Models to Interrogate Small Molecule Inhibition of the MAPK Pathway
by Lesley A. Mathews Griner, PhD of Novartis Institutes for Biomedical Research



Organoids, a Disease and Patient Specific In Vitro Model System
by Robert Vries, PhD of Hubrecht Organoid Technology (HUB)

Plus 3 podium presentations selected from submitted abstracts

Toxicology/Safety



The Age of Organoids – 21st Century Cell Culture for 21st Century Science
by Thomas Hartung, MD PhD of Johns Hopkins Bloomberg School of Public Health



Physiological and Toxicological Evaluation of Advanced In Vitro 3D Liver Models for Toxicological Profiling in the Pharmaceutical Industry
by Philip Hewitt, PhD of Merck KGaA



3D HepaRG Spheroids Model Physiologically-relevant Levels of Xenobiotic Metabolism and Tissue-like Functionality for Tox21 Screening
by Stephen S. Ferguson, PhD of National Institute of Environmental Health Sciences (NIEHS)

Plus 3 podium presentations selected from submitted abstracts

Light breakfast, lunch, and post-conference networking reception included.

Organized by:

InSphero AG, Centers for Alternatives to Animal Testing (CAAT),
National Center for Advancing Translational Sciences (NCATS), and
Promega Corp.